Janice S Withycombe1,2, Aimee Carlson3, Carly Coleman4, Sharon L Leslie5, Micah Skeens6, Hanna Tseitlin7, Elizabeth A Duffy8. 1. Clemson University, Clemson, SC, USA. 2. Bi-Lo Charities Children's Cancer Center, Greenville, SC, USA. 3. Cleveland Clinic Children's Hospital, Cleveland, OH, USA. 4. Cohen Children's Medical Center, New Hyde Park, NY, USA. 5. Emory University, Atlanta, GA, USA. 6. Nationwide Children's Hospital, Columbus, OH, USA. 7. McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada. 8. University of Michigan School of Nursing, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Immunotherapy is a new and promising approach to treating pediatric cancers. These types of therapies have unique mechanisms of action for identifying and fighting cancer, as compared with traditional chemotherapy, and therefore are associated with different therapy-related adverse events (AEs). The purpose of this systematic review was to review available evidence to: (a) identify commonly reported AEs associated with immunotherapy agents frequently used in pediatric oncology and (b) generate recommendations for nursing practice. METHOD: A clinical question was developed and used to guide the systematic literature review. Five immunotherapy agents (dinutuximab, blinatumomab, rituximab, inotuzumab ozogamicin, brentuximab vedotin) were selected for inclusion secondary to their high relevance to pediatric oncology. A literature search was conducted to locate articles published between January 1, 2003 and October 31, 2018. RESULTS: Seventeen articles met eligibility criteria for inclusion and were evaluated using the Grading of Recommendations Assessment, Development, and Evaluation criteria. The most commonly reported AEs for the selected immunotherapy agents were identified and summarized. Strong recommendations are made for nurses to become familiar with the unique AE profiles associated with individual immunotherapy agents. Agent-specific recommendations for nursing practice regarding AEs associated with dinutuximab and rituximab were generated. CONCLUSIONS: Immunotherapy is rapidly emerging as an effective therapy for pediatric cancers. Nurses need to be aware of the breadth of agent-specific, immunotherapy-related AEs to appropriately monitor and manage patients receiving these therapies. Additional work is needed to confidently profile immunotherapy-related AEs in pediatric oncology and to develop agent-specific educational materials for patients/families.
BACKGROUND: Immunotherapy is a new and promising approach to treating pediatric cancers. These types of therapies have unique mechanisms of action for identifying and fighting cancer, as compared with traditional chemotherapy, and therefore are associated with different therapy-related adverse events (AEs). The purpose of this systematic review was to review available evidence to: (a) identify commonly reported AEs associated with immunotherapy agents frequently used in pediatric oncology and (b) generate recommendations for nursing practice. METHOD: A clinical question was developed and used to guide the systematic literature review. Five immunotherapy agents (dinutuximab, blinatumomab, rituximab, inotuzumab ozogamicin, brentuximab vedotin) were selected for inclusion secondary to their high relevance to pediatric oncology. A literature search was conducted to locate articles published between January 1, 2003 and October 31, 2018. RESULTS: Seventeen articles met eligibility criteria for inclusion and were evaluated using the Grading of Recommendations Assessment, Development, and Evaluation criteria. The most commonly reported AEs for the selected immunotherapy agents were identified and summarized. Strong recommendations are made for nurses to become familiar with the unique AE profiles associated with individual immunotherapy agents. Agent-specific recommendations for nursing practice regarding AEs associated with dinutuximab and rituximab were generated. CONCLUSIONS: Immunotherapy is rapidly emerging as an effective therapy for pediatric cancers. Nurses need to be aware of the breadth of agent-specific, immunotherapy-related AEs to appropriately monitor and manage patients receiving these therapies. Additional work is needed to confidently profile immunotherapy-related AEs in pediatric oncology and to develop agent-specific educational materials for patients/families.
Authors: Gordon Guyatt; Andrew D Oxman; Elie A Akl; Regina Kunz; Gunn Vist; Jan Brozek; Susan Norris; Yngve Falck-Ytter; Paul Glasziou; Hans DeBeer; Roman Jaeschke; David Rind; Joerg Meerpohl; Philipp Dahm; Holger J Schünemann Journal: J Clin Epidemiol Date: 2010-12-31 Impact factor: 6.437
Authors: Bernadette Mazurek Melnyk; Ellen Fineout-Overholt; Susan B Stillwell; Kathleen M Williamson Journal: Am J Nurs Date: 2010-01 Impact factor: 2.220
Authors: Abdulmunem M Abulayha; Salah A Tabal; Eman I Shawesh; Mohamed A Elbasir; Abdulrhman S Elbanani; Yosra M Lamami; Amin Bredan Journal: Leuk Res Date: 2009-07-05 Impact factor: 3.156
Authors: Franco Locatelli; Christine Mauz-Koerholz; Kathleen Neville; Anna Llort; Auke Beishuizen; Stephen Daw; Marta Pillon; Nathalie Aladjidi; Thomas Klingebiel; Judith Landman-Parker; Aurora Medina-Sanson; Keith August; Jessica Sachs; Kristen Hoffman; Judith Kinley; Sam Song; Gregory Song; Stephen Zhang; Ajit Suri; Lia Gore Journal: Lancet Haematol Date: 2018-10 Impact factor: 18.959
Authors: Araz Marachelian; Ami Desai; Frank Balis; Howard Katzenstein; Muna Qayed; Michael Armstrong; Kathleen A Neville; Susan L Cohn; Mark Bush; Rudy Gunawan; Allison Pecha Lim; Malcolm A Smith; L Mary Smith Journal: Cancer Chemother Pharmacol Date: 2016-01-20 Impact factor: 3.333
Authors: M Fevzi Ozkaynak; Andrew L Gilman; Wendy B London; Arlene Naranjo; Mitchell B Diccianni; Sheena C Tenney; Malcolm Smith; Karen S Messer; Robert Seeger; C Patrick Reynolds; L Mary Smith; Barry L Shulkin; Marguerite Parisi; John M Maris; Julie R Park; Paul M Sondel; Alice L Yu Journal: Front Immunol Date: 2018-06-18 Impact factor: 7.561